Enter your login e-mail to the account
Search
Search parameters
Search results
- Secondary osteoporosis in patients with malignancies
MUDr. Beata Špániková, PhD.
(1/2018, Interdisciplinary consilium )
- Impact of CDK 4/6 inhibitors on overall survival of patients with advanced breast cancer – in the light of new data
MUDr. Bibiána Vertáková Krakovská, PhD.
(2/2024, Company information ) - Current recommendations for bisphosphonates therapy in cancer patients
prof. MUDr. Stanislav Špánik, CSc., MUDr. Beata Špániková, PhD.
(6/2013, Review articles ) - An update in breast cancer treatment
MUDr. Markéta Palácová
(4/2007, Review articles ) - Treatment of HR+, HER2- advanced/metastatic breast cancer according to ESO-ESMO recommendations ABC 5
MUDr. Soňa Johnová, MUDr. Soňa Huľová
(2/2021, Review articles ) - Nové perspektívy v liečbe pokročilého a metastatického HR+ HER2- karcinómu prsníka
MUDr. Miroslava Malejčíková, MUDr. Silvia Jurišová
(2/2018, Review articles ) - Dual inhibition after failure of NSAI as a solution to hormone therapy resistance
MUDr. Bibiána Vertáková Krakovská, PhD.
(1/2015, Review articles ) - Postavenie inhíbitorov aromatázy v adjuvantnej liečbe potmenopauzálnych žien s hormonálne pozitívnym karcinómom prsníka
MUDr. Jana Obertová
(2/2009, Review articles ) - Breast cancers in erderly women
doc. MUDr. Mária Wagnerová, CSc., doc. MUDr. Alexander Berč, CSc.
(2/2009, Review articles ) - The efect of CDK 4/6 inhibition on overal survival in metastatic breast cancer
MUDr. Bibiána Vertáková Krakovská, PhD.
(2/2020, Review articles ) - Publikujeme v zahraničí
(4/2016, Information & comments ) - CHEMOPREVENTION OF BREAST CANCER
prof. MUDr. Ľudovít M. Jurga, DrSc., prof. MUDr. Myrón Malý, CSc.
(5/2007, Review articles ) - Faslodex 500 and new treatment options
MUDr. Katarína Petráková
(6/2010, Drugs & drug classes ) - Ribociclib, inhibitor of cyclin-dependent kinases 4 and 6, in the treatment of HR+/HER2 - advanced breast cancer
MUDr. Mária Rečková
(1/2017, Drugs & drug classes ) - Abemaciclib in first-line treatment of HR+, HER2- breast cancer with visceral metastases in a premenopausal patient
MUDr. Soňa Johnová, MUDr. Soňa Huľová
(3/2022, Case reports ) - Principles of hormonal therapy and chemotherapy in the treatment of metastatic HR+, HER2- breast cancer
MUDr. Miroslava Malejčíková
(6/2018, Review articles ) - Experience with exemestane in daily practise
MUDr. Jana Obertová, MUDr. Ivana Zigová
(3/2009, Original articles & case reports )